Search Results - "Yogo, Naoyuki"

Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study by Hase, Tetsunari, Miyazaki, Masayuki, Ichikawa, Kazuya, Yogo, Naoyuki, Ozawa, Naoya, Hatta, Takahiro, Ando, Masahiko, Sato, Mitsuo, Kondo, Masashi, Yamada, Kiyofumi, Hasegawa, Yoshinori

“…Background Intravenous administration of magnesium with a short hydration regimen is recommended for patients receiving high-dose cisplatin to protect against…”
Get full text

High-performance glass filters for capturing and culturing circulating tumor cells and cancer-associated fibroblasts by Tanaka, Hiromasa, Iwata, Daijiro, Shibata, Yuki, Hase, Tetsunari, Onoshima, Daisuke, Yogo, Naoyuki, Shibata, Hirofumi, Sato, Mitsuo, Ishikawa, Kenji, Nagasawa, Ikuo, Hasegawa, Yoshinori, Ishii, Makoto, Baba, Yoshinobu, Hori, Masaru

“…Various liquid biopsy methods have been developed for the non-invasive and early detection of diseases. In particular, the detection of circulating tumor cells…”
Get full text

Growth inhibitory effects of miR‐221 and miR‐222 in non‐small cell lung cancer cells by Yamashita, Ryo, Sato, Mitsuo, Kakumu, Tomohiko, Hase, Tetsunari, Yogo, Naoyuki, Maruyama, Eiichi, Sekido, Yoshitaka, Kondo, Masashi, Hasegawa, Yoshinori

“…Both pro‐ and anti‐oncogenic roles of miR‐221 and miR‐222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic…”
Get full text

Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients by Yogo, Naoyuki, Hase, Tetsunari, Kasama, Toshihiro, Nishiyama, Keine, Ozawa, Naoya, Hatta, Takahiro, Shibata, Hirofumi, Sato, Mitsuo, Komeda, Kazuki, Kawabe, Nozomi, Matsuoka, Kohei, Chen-Yoshikawa, Toyofumi Fengshi, Kaji, Noritada, Tokeshi, Manabu, Baba, Yoshinobu, Hasegawa, Yoshinori

“…Detecting molecular targets in specimens from patients with lung cancer is essential for targeted therapy. Recently, we developed a highly sensitive,…”
Get full text

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer by Hatta, Takahiro, Hase, Tetsunari, Hara, Toru, Kimura, Tomoki, Kojima, Eiji, Abe, Takashi, Horio, Yoshitsugu, Goto, Yasuhiro, Ozawa, Naoya, Yogo, Naoyuki, Shibata, Hirofumi, Shimokata, Tomoya, Oguri, Tetsuya, Yamamoto, Masashi, Yanagisawa, Kiyoshi, Ando, Masahiko, Ando, Yuichi, Kondo, Masashi, Ishii, Makoto, Hasegawa, Yoshinori

“…Background The Cockcroft–Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where…”
Get full text

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer by Kakumu, Tomohiko, Sato, Mitsuo, Goto, Daiki, Kato, Toshio, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Fukui, Takayuki, Yokoi, Kohei, Sekido, Yoshitaka, Girard, Luc, Minna, John D., Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Kondo, Masashi, Hasegawa, Yoshinori

“…To identify potential therapeutic targets for lung cancer, we performed semi‐genome‐wide shRNA screening combined with the utilization of genome‐wide…”
Get full text

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors by Yamamoto, Takafumi, Ito, Takanori, Hase, Tetsunari, Ishigami, Masatoshi, Mizuno, Kazuyuki, Yamamoto, Kenta, Imai, Norihiro, Ishizu, Yoji, Honda, Takashi, Shibata, Hirofumi, Hatta, Takahiro, Yogo, Naoyuki, Yasuda, Satoshi, Toyoda, Hidenori, Abe, Takashi, Kawashima, Hiroki, Hashimoto, Naozumi, Fujishiro, Mitsuhiro

“…It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients…”
Get full text

Comparing incidences of infusion site reactions between brand‐name and generic vinorelbine in patients with non‐small cell lung cancer by Ozawa, Naoya, Hase, Tetsunari, Hatta, Takahiro, Sagara, Atsunobu, Ichikawa, Kazuya, Miyazaki, Masayuki, Yogo, Naoyuki, Ando, Masahiko, Hashimoto, Naozumi, Yamada, Kiyofumi, Hasegawa, Yoshinori

“…Aim This study aimed to compare the incidence of infusion site reactions (ISRs) induced by intravenous administration of brand‐name and generic vinorelbine…”
Get full text

eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer by Tanaka, Ichidai, Sato, Mitsuo, Kato, Toshio, Goto, Daiki, Kakumu, Tomohiko, Miyazawa, Ayako, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Sekido, Yoshitaka, Girard, Luc, Minna, John D., Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Kondo, Masashi, Hasegawa, Yoshinori

“…To identify novel therapeutic targets for non‐small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification…”
Get full text

Abstract 206: Cytochrome c oxidase subunit 5a (COX5A) is identified as a potential therapeutic target for lung cancer with high therapeutic index through a pooled shRNA screen by Kato, Toshio, Sato, Mitsuo, Kondo, Masashi, Kakumu, Tomohiko, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Hasegawa, Yoshionori, Minnna, John D., Girard, Luc

“…[Background]Recent advances in high throughput analysis of genetic and epigenetic alterations revealed numerous changes in lung cancer cells. It is vital to…”
Get full text

Identification of proteasomal catalytic subunit PSMA 6 as a therapeutic target for lung cancer by Kakumu, Tomohiko, Sato, Mitsuo, Goto, Daiki, Kato, Toshio, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Fukui, Takayuki, Yokoi, Kohei, Sekido, Yoshitaka, Girard, Luc, Minna, John D., Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Kondo, Masashi, Hasegawa, Yoshinori

“…To identify potential therapeutic targets for lung cancer, we performed semi‐genome‐wide sh RNA screening combined with the utilization of genome‐wide…”
Get full text

eIF 2 β, a subunit of translation‐initiation factor EIF 2, is a potential therapeutic target for non‐small cell lung cancer by Tanaka, Ichidai, Sato, Mitsuo, Kato, Toshio, Goto, Daiki, Kakumu, Tomohiko, Miyazawa, Ayako, Yogo, Naoyuki, Hase, Tetsunari, Morise, Masahiro, Sekido, Yoshitaka, Girard, Luc, Minna, John D., Byers, Lauren A., Heymach, John V., Coombes, Kevin R., Kondo, Masashi, Hasegawa, Yoshinori

“…To identify novel therapeutic targets for non‐small cell lung cancer ( NSCLC ), we conducted an integrative study in the following 3 stages: (i) identification…”
Get full text